Deciphera Pharmaceuticals Ownership

DCPHDelisted Stock  USD 13.32  0.36  2.63%   
Deciphera Pharmaceuticals holds a total of 86.48 Million outstanding shares. The majority of Deciphera Pharmaceuticals LLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Deciphera Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Deciphera Pharmaceuticals. Please pay attention to any change in the institutional holdings of Deciphera Pharmaceuticals LLC as this could imply that something significant has changed or is about to change at the company. Also note that almost four hundred fourty-one thousand twenty-eight invesors are currently shorting Deciphera Pharmaceuticals expressing very little confidence in its future performance.
Some institutional investors establish a significant position in stocks such as Deciphera Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Deciphera Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Deciphera Stock Ownership Analysis

About 28.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.21. Deciphera Pharmaceuticals had not issued any dividends in recent years. Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 280 people. To learn more about Deciphera Pharmaceuticals LLC call Steven Hoerter at 781 209 6400 or check out https://www.deciphera.com.

Deciphera Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Deciphera Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Deciphera Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Deciphera Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Deciphera Pharmaceuticals Outstanding Bonds

Deciphera Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Deciphera Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Deciphera bonds can be classified according to their maturity, which is the date when Deciphera Pharmaceuticals LLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in Deciphera Stock

If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Volatility Analysis
Get historical volatility and risk analysis based on latest market data